IMPACT INVESTING IN THE FUTURE of MENTAL HEALTH & NEUROSCIENCE

Fall 2025




Psychedelic Science Institute Launched in July 2025

Be a founding supporter of PSI via the nonprofit Psychedelic Innovation Fund (PIF).

To date we have raised \$1.2 million.

Your gift or grant will help close the final \$1M needed to reach our \$2.2M goal for 2025, supporting the launch of PSI's first two TRIP Clinics in Santa Monica and Hollywood, CA.



Why PSI, Why Now

We are amid a national mental health crisis. Millions struggle with depression, anxiety, addiction and PTSD, yet current treatments are often ineffective or poorly tolerated.

A resurgence in psychedelic-based therapies with medicines such as psilocybin, LSD and MDMA offer promising alternatives for these conditions and others such as cognitive decline, traumatic brain injury, stroke and chronic pain.

Experienced teams of clinician-scientists and mental health experts are urgently needed to help bring these paradigm-shifting approaches through FDA approval and into real-world practice.

That's why we launched PSI in July 2025, one of California's first research-driven clinical trial and treatment networks dedicated to psychedelic-assisted therapies.

Our Vision

PSI's TRIP Clinics in Santa Monica and Hollywood are the foundation of a scalable model that will:

- Conduct clinical trials for mental health and other brain conditions
- 2. Provide ketamine-assisted psychotherapy (KAP) for patients in need
- 3. Train the next generation of psychedelic therapists and researchers
- 4. Develop affordable, evidence-based care models



of MENTAL HEALTH & NEUROSCIENCE



Founding Team

A multidisciplinary group with decades of leadership in neuroscience, mental health, psychedelic clinical trials and healthcare innovation.



Daniel Kelly, MD CHIEF EXECUTIVE OFFICER



Keith Heinzerling, MD CHIEF MEDICAL & SCIENCE OFFICER



Brooke Balliett, LMFT CHIEF OPERATING OFFICER



Micah Linton, PsyD CHIEF CLINICAL & INNOVATION OFFICER



Greg Kearns, MHACHIEF STRATEGY
& BUSINESS DEV.

Your 2025 Gift Will

- Sustain research and caregiver teams at our first two TRIP Clinics
- Keep clinics fully operational and FDA/DEA compliant
- Expand outreach to patients and providers

Future Gifts Will

- Launch investigator-initiated clinical trials
- Provide education & training in psychedelic medicine
- Support access to psychedelic-assisted therapies for the underserved

Your Opportunity to Make an Impact This Year

Funding Goal 2025: \$2.2M; Raised: \$1.2M;
 Still Needed: \$1M by year-end

Giving Options via PIF*

- Direct Cash Donations
- Private Foundation Grants
- Recoverable Grants
- Donor-Advised Funds (DAFs)
- *PIF is a fiscal sponsorship program of Legacy Global Programs, a public 501(c)(3).

Partner With Us

Help bring data-driven psychedelic-based care into the mainstream as we position PSI to be California's leading clinical trial and treatment network for mental health innovation.

Contact:

Daniel Kelly, MD dkelly@psychedelicsci.com **Greg Kearns, MHA** gkearns@psychedelicsci.com **Mike Avila** mavila@psychedelicsci.com

Learn more at:

www.lohas.org/client/psychedelic-innovation-fund



Early Accomplishments Fueled by PIF



July-September 2025

CLINICS OPENED

• 2 PSI TRIP Clinics in Santa Monica & Hollywood

TEAM GROWTH

• 9 full-time staff & 5 contractors hired

CLINICAL TRIALS

- 3 industry-sponsored trials launched in August/September:
 - MindMed MM120-301:
 LSD for generalized anxiety disorder
 - Usona PSIL301: Psilocybin for major depression
 - Atai VLS-01-201:

 DMT for treatment-resistant depression
- 3 additional trials launching in Q4 2025 with Cybin & Mindmed

MENTAL HEALTH SERVICES

 134 ketamine-assisted psychotherapy (KAP) sessions provided

COMMUNITY OUTREACH & EDUCATION

- PSI website launched
- Outreach to over 1600 LA-based providers initiated
- PSI Learning Center & first two blogs launched

